We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01394796
Recruitment Status : Completed
First Posted : July 14, 2011
Last Update Posted : March 13, 2013
Information provided by:
Parc de Salut Mar

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : February 2011
  Study Completion Date : February 2011

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 February 9, 2016 March 9, 2016
2 March 18, 2016 April 20, 2016
3 February 9, 2017 March 28, 2017